Drug development for poorly soluble, high-dose, and structurally complex molecules has outgrown the traditional siloed model in which particle engineering (PE) and formulation development (FD) operate as sequential, independent disciplines. This separation introduces avoidable risks: suboptimal bioavailability, poor manufacturability, delayed timelines, and compounding CMC uncertainty.
This whitepaper argues that tight integration of drug substance (DS) particle engineering with formulation development, analytical sciences, and manufacturing—within a CRDMO ecosystem—is no longer a differentiator. It is a strategic necessity. An integrated model can compress timelines by two to three months, improve first-time-right manufacturing success, and meaningfully reduce late-stage CMC risk—particularly for enabling technologies such as spray-dried dispersion (SDD), micronization, nano-sizing and spherical crystallization.
Historically, drug development has been organized as a linear handoff across discrete functional stages:
This linear model assumes that outputs from one stage are clearly transferable downstream. In practice, the assumption does not hold.
Particle attributes are not formulation-agnostic. The process history of a DS— how it was spray-dried, milled or crystallized—directly determines its tabletability, dissolution behaviour, and chemical stability. When particle engineering decisions are made without downstream formulation endpoints in view, the consequence is rework: dissolution failures at scale, unexpected solid-state instability, and compressed IND timelines that force reactive problem-solving rather than proactive risk mitigation.
The challenge is particularly acute with enabling technologies. Spray-dried dispersions (SDDs), nano-milled particles, and spherically crystallized materials frequently demonstrate acceptable critical quality attributes (CQAs) at laboratory scale, only to exhibit divergent behavior at engineering scale — driven by differences in particle microstructure, bulk and tap density, porosity, and the spatial distribution of drug substance within the drug product matrix. These are not unpredictable failures. They are foreseeable consequences of a development model that separates decisions that are fundamentally interdependent.
An integrated model is not just co-location, it is scientific and operational convergence— across design, data flows, and iterative process loops.
In an integrated model, the particle engineering (PE) decisions— solvent system selection, drying kinetics, particle size distribution (PSD) targets— are made with formulation endpoints explicitly in scope. Target product profile (TPP) and manufacturability constraints are established early and shared across functions. Solid-state characterization data, biopharmaceutical assessments, and formulation screening outputs flow between teams as shared scientific currency rather than sequential deliverables.
On the process side, integration implies iterative loops between upstream unit operations—spray drying, crystallization, milling—and downstream ones: blending, granulation, compression. Tabletability and compressibility data from formulation development inform milling endpoint targets. Dissolution profiles and supersaturation behavior inform amorphous dispersion design. Physical stability readouts feed back into process conditions — before problems escalate into program-level risks.
Organizationally, integration also requires genuine cross-functional ownership, with process engineering, particle science, Pre-formulation (PFD), Formulation R&D (FRD), Analytical R&D (ARD) and GMP Manufacturing (FMF) operating under shared accountability rather than sequential handoffs. Single project governance across the DS–DP interface is both an enabler and a cultural requirement.
A fully integrated CRDMO is uniquely positioned to operationalize this model. Key structural enablers include end-to-end infrastructure spanning pre-formulation through pilot GMP manufacturing; unified project governance with single accountability across the DS–DP interface; and dedicated technology platforms — including SDD, micronization using air jet mill, nano-sizing via wet bead milling and high-pressure homogenization.
The value creation enabled by this model is most clearly illustrated by comparing development outcomes across approaches:
| Stage | Traditional Model | Integrated CRDMO Model |
| Pre-formulation | Isolated physicochemical characterization | Hypothesis-driven, formulation-linked screening |
| Particle engineering | Solubility and dissolution focus | Solubility + manufacturability + physical stability |
| Formulation | Downstream adaptation to DS outputs | Co-designed with particle engineering inputs |
| Scale-up | Late-stage surprises | De-risked via early engineering batches |
| IND readiness | Sequential and timeline-compressed | Parallelized and accelerated |
Sponsors frequently approach development partners with partial process characterization data or overconfidence in early results, or an established process that has not been stress-tested against manufacturing scale constraints. An integrated CRDMO must be positioned — and willing — to constructively challenge these assumptions and co-design a risk-mitigated development pathway from the outset.
This requires a fundamental shift in how CRDMOs engages:
| Execution Model | Integrated Model |
| Sponsors dictate experiments | CRDMO co-defines the scientific strategy |
| Limited scope (e.g., formulation only) | End-to-end program ownership |
| Reactive problem-solving | Proactive risk identification and mitigation |
| Transactional | Consultative and scientifically accountable |
Particle engineering and formulation development are two sides of the same coin. Treating them as independent workstreams introduces inefficiencies and risks that modern drug development programs— can no longer afford.
An integrated CRDMO ecosystem, spanning from early developability assessment through GMP manufacturing, enables faster development timelines, more robust robust and manufacturable drug products, and meaningfully lower CMC risk at every stage. Ultimately, this model transforms the CRDMO from a service provider into a strategic partner— one capable of guiding sponsors from molecule to clinic with rigor and program-level accountability.
